Results 81 to 90 of about 85,335 (283)

Tacrolimus-Associated Dilated Cardiomyopathy in Adult Patient After Orthotopic Liver Transplant

open access: yesJournal of Investigative Medicine High Impact Case Reports, 2017
This report presents a case of tacrolimus cardiotoxicity in an adult patient who received tacrolimus immunosuppression for orthotopic liver transplant (OLT).
Jennifer McLeod MD   +3 more
doaj   +1 more source

An Elastomeric Polymer Matrix, PEUU-Tac, Delivers Bioactive Tacrolimus Transdurally to the CNS in Rat

open access: yesEBioMedicine, 2017
Central nervous system (CNS) neurons fail to regrow injured axons, often resulting in permanently lost neurologic function. Tacrolimus is an FDA-approved immunosuppressive drug with known neuroprotective and neuroregenerative properties in the CNS ...
Yolandi van der Merwe   +12 more
doaj   +1 more source

Tacrolimus ointment in the management of atopic dermatitis

open access: yes, 2009
Antonello Baldo, Mariana Cafiero, Paola Di Caterino, Luisa Di CostanzoDepartment of Dermatology, University of Naples Federico II, Naples, ItalyAbstract: Atopic dermatitis (AD) is a chronic, relapsing, highly pruritic inflammatory skin disease.
Paola Di Caterino   +3 more
core  

Dispensing of actionable pharmacogenetic drugs among adults receiving cardiovascular disease medications in the Northern Netherlands: A serial cross‐sectional study

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
The extent of pharmacogenetic (PGx) drug dispensing among Dutch adults receiving medications for cardiovascular disease (CVD) is unknown. Using the University of Groningen IADB.nl pharmacy database, we performed a serial cross‐sectional study (2019–2023) to estimate the annual prevalence of PGx drug dispensing and annual rates of initiation.
Zhuolin Zhang   +5 more
wiley   +1 more source

Topical tacrolimus : efficacy and tolerability

open access: yes, 2013
Tacrolimus, formulated as a 0.1% or 0.03% ointment, is the first topical immunosuppressant to receive widespread regulatory approval. Currently, it is only approved for the second-line treatment of moderate or severe atopic eczema in adults and children >
Lee, Frederick J.   +1 more
core  

Modifying Tacrolimus-related Toxicity After Liver Transplantation Comparing Life Cycle Pharma Tacrolimus Versus Extended-released Tacrolimus: A Multicenter, Randomized Controlled Trial [PDF]

open access: yes
Background:The aim of this open-label, multicenter, randomized controlled study was to investigate whether the life cycle pharma (LCP)-tacrolimus compared with the extended-release (ER)-tacrolimus formulation results in a difference in the prevalence of ...
de Winter, Brenda C.M.; id_orcid   +41 more
core   +2 more sources

The impact of tacrolimus therapy on the outcomes of vernal keratoconjunctivitis: a systematic review and meta-analysis

open access: yesFrontiers in Medicine
BackgroundVarious preparations of tacrolimus have been implemented for patients with vernal keratoconjunctivitis (VKC). However, there is a lack of evidence regarding the safety and effectiveness of different dosages and forms of tacrolimus for patients ...
Reem AlHuthail
doaj   +1 more source

Overview of extended release tacrolimus in solid organ transplantation. [PDF]

open access: yes, 2016
Tacrolimus (Prograf(©), Astellas Pharma Europe Ltd, Staines, United Kingdom; referred to as tacrolimus-BID) is an immunosuppressive agent to prevent and treat allograft rejection in kidney transplant recipients in combination with mycophenolate mofetil ...
Joshua Rusinak (12544975)   +5 more
core   +1 more source

Tacrolimus—finally! [PDF]

open access: yesGut, 2006
K R, Herrlinger   +2 more
openaire   +2 more sources

Role of tacrolimus combination therapy with mycophenolate mofetil in the prevention of organ rejection in kidney transplant patients

open access: yes, 2010
P Dalal1, G Shah1, D Chhabra2, Lorenzo Gallon21Department of Medicine, Mount Sinai Hospital, Chicago; 2Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USAIntroduction: Several new medications are now available for ...
P Dalal, D Chhabra, G Shah, et al
core  

Home - About - Disclaimer - Privacy